Int Ophthalmol:不使用眼科手术粘连设备进行人工晶状体植入术

2017-04-08 luowenbo MedSci原创

本研究目的在于确定在不使用眼科手术粘连设备时能否安全植入单片亲水性丙烯酸酯人工晶状体。该回顾性研究中包括经白内障超声乳化和不使用眼科手术粘连设备的人工晶状体植入术的100眼,使用眼科手术粘连设备进行人工晶状体植入术的80眼作为对照组。

不使用眼科手术粘连设备进行人工晶状体植入术

本研究目的在于确定在不使用眼科手术粘连设备时能否安全植入单片亲水性丙烯酸酯人工晶状体。该回顾性研究中包括经白内障超声乳化和不使用眼科手术粘连设备的人工晶状体植入术的100眼,使用眼科手术粘连设备进行人工晶状体植入术的80眼作为对照组。

在人工晶状体植入术中,利用冲洗套管与前房相连,通过透镜注射器植入人工晶状体。在术前与术后1、7、 30天分别测量视力、角膜清晰度、水肿、眼压和角膜内皮细胞计数。术后两周重复进行一次角膜内皮细胞计数,评估手术并发症。人工晶状体移植术没有观察到严重的并发症,如:后囊破裂、人工晶状体锁眼、悬韧带断裂、Descemet撕裂或脱离等。术后的第七天,90%的眼睛达到20/20甚至更好的视力。使用眼科手术粘连设备与否并不影响角膜内皮细胞的损失量(P=0.356)。不使用眼科手术粘连设备植入人工晶状体并未发生严重并发症。不使用眼科手术粘连设备进行人工晶状体植入术的可能的优点有,手术时间更短,避免术后因眼科手术粘连设备残留引起的眼内压(IOP)反弹,降低手术成本。

原文出处:


本文系梅斯医学(MedSci)原创编译,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1994626, encodeId=61851994626bf, content=<a href='/topic/show?id=b3e7e2866ea' target=_blank style='color:#2F92EE;'>#眼科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72866, encryptionId=b3e7e2866ea, topicName=眼科手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Feb 09 19:00:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946315, encodeId=61ab19463158c, content=<a href='/topic/show?id=6aad2480499' target=_blank style='color:#2F92EE;'>#人工晶状体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24804, encryptionId=6aad2480499, topicName=人工晶状体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Feb 07 08:00:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520355, encodeId=c74215203558f, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Sun Apr 09 15:00:00 CST 2017, time=2017-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541185, encodeId=2b1a1541185f9, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sun Apr 09 15:00:00 CST 2017, time=2017-04-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1994626, encodeId=61851994626bf, content=<a href='/topic/show?id=b3e7e2866ea' target=_blank style='color:#2F92EE;'>#眼科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72866, encryptionId=b3e7e2866ea, topicName=眼科手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Feb 09 19:00:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946315, encodeId=61ab19463158c, content=<a href='/topic/show?id=6aad2480499' target=_blank style='color:#2F92EE;'>#人工晶状体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24804, encryptionId=6aad2480499, topicName=人工晶状体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Feb 07 08:00:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520355, encodeId=c74215203558f, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Sun Apr 09 15:00:00 CST 2017, time=2017-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541185, encodeId=2b1a1541185f9, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sun Apr 09 15:00:00 CST 2017, time=2017-04-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1994626, encodeId=61851994626bf, content=<a href='/topic/show?id=b3e7e2866ea' target=_blank style='color:#2F92EE;'>#眼科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72866, encryptionId=b3e7e2866ea, topicName=眼科手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Feb 09 19:00:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946315, encodeId=61ab19463158c, content=<a href='/topic/show?id=6aad2480499' target=_blank style='color:#2F92EE;'>#人工晶状体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24804, encryptionId=6aad2480499, topicName=人工晶状体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Feb 07 08:00:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520355, encodeId=c74215203558f, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Sun Apr 09 15:00:00 CST 2017, time=2017-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541185, encodeId=2b1a1541185f9, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sun Apr 09 15:00:00 CST 2017, time=2017-04-09, status=1, ipAttribution=)]
    2017-04-09 jiyangfei
  4. [GetPortalCommentsPageByObjectIdResponse(id=1994626, encodeId=61851994626bf, content=<a href='/topic/show?id=b3e7e2866ea' target=_blank style='color:#2F92EE;'>#眼科手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72866, encryptionId=b3e7e2866ea, topicName=眼科手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Feb 09 19:00:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946315, encodeId=61ab19463158c, content=<a href='/topic/show?id=6aad2480499' target=_blank style='color:#2F92EE;'>#人工晶状体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24804, encryptionId=6aad2480499, topicName=人工晶状体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Feb 07 08:00:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520355, encodeId=c74215203558f, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Sun Apr 09 15:00:00 CST 2017, time=2017-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541185, encodeId=2b1a1541185f9, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sun Apr 09 15:00:00 CST 2017, time=2017-04-09, status=1, ipAttribution=)]